AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2680154 — intervention group
Group type: EXPERIMENTAL
Intervention: PYR 800 mg with NQ 80 mg
Number of subjects: 118
Study 2680154 — intervention group
Group type: COMPARATOR
Intervention: PYR 1,200 mg alone
Number of subjects: 118
Study 814106 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluspirilene
Number of subjects: 332
Study 814106 — intervention group
Group type: EXPERIMENTAL
Intervention: Penfluridol
Number of subjects: 332
Study 814106 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine-decanoate
Number of subjects: 332
Study 814106 — intervention group
Group type: COMPARATOR
Intervention: Flupenthixol-decanoate
Number of subjects: 332
Study 31180194 — intervention group
Group type: EXPERIMENTAL
Intervention: Teplizumab
Number of subjects: 76
Study 31180194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 27974345 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 8410
Study 27974345 — intervention group
Group type: COMPARATOR
Intervention: Other biomarkers
Number of subjects: 8410
Study 25566874 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention (self-monitoring for the first week of each month and individualized treatment self-titration schedule)
Number of subjects: 263
Study 25566874 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention
Number of subjects: 263
Study 24165817 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (TCI) of propofol with alfentanil
Number of subjects: 220
Study 24165817 — intervention group
Group type: COMPARATOR
Intervention: Manually controlled infusion (MCI) of propofol with alfentanil
Number of subjects: 220
Study 22159679 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored newsletter
Number of subjects: 329
Study 22159679 — intervention group
Group type: COMPARATOR
Intervention: Targeted newsletter
Number of subjects: 329
Study 22159679 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading the newsletter
Number of subjects: 329
Study 22159679 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning to make an appointment for a DFE
Number of subjects: 329
Study 19364980 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (50, 100, or 300 mg/d for 2 weeks)
Number of subjects: 60
Study 16464988 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (ETN) monotherapy
Number of subjects: 315
Study 16464988 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) plus methotrexate (MTX)
Number of subjects: 315
Study 14998986 — intervention group
Group type: COMPARATOR
Intervention: Linezolid 600 mg every 12 h
Number of subjects: 40
Study 14998986 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinupristin-dalfopristin 7.5 mg/kg every 8 h
Number of subjects: 40
Study 14998986 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinupristin-dalfopristin
Number of subjects: 40
Study 14998986 — intervention group
Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 40
Study 11392625 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 0
Study 11392625 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin
Number of subjects: 0
Study 9455715 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbopol matrix tablet with normal diet
Number of subjects: 12
Study 9455715 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbopol matrix tablet with high fat diet
Number of subjects: 12
Study 9455715 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbopol matrix tablet with high fat/high protein diet
Number of subjects: 12
Study 9455715 — intervention group
Group type: COMPARATOR
Intervention: Lipid matrix tablet with fasting condition
Number of subjects: 12
Study 9455715 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid matrix tablet with normal diet
Number of subjects: 12
Study 9455715 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid matrix tablet with high fat diet
Number of subjects: 12
Study 9455715 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid matrix tablet with high fat/high protein diet
Number of subjects: 12
Study 8189563 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E1 (0, 2.5, 5.0, 7.5, and 10 micrograms)
Number of subjects: 15
Study 8189563 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 15
Study 3074922 — intervention group
Group type: EXPERIMENTAL
Intervention: White spaghetti
Number of subjects: 13
Study 3074922 — intervention group
Group type: COMPARATOR
Intervention: Potato
Number of subjects: 13
Study 3074922 — intervention group
Group type: COMPARATOR
Intervention: White bread
Number of subjects: 13
Study 3074922 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato with bolognese sauce
Number of subjects: 13
Study 3074922 — intervention group
Group type: EXPERIMENTAL
Intervention: White spaghetti with bolognese sauce
Number of subjects: 13
Study 30590573 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1000 mg) taken 1 hour prior to pain rating
Number of subjects: 60
Study 30590573 — intervention group
Group type: COMPARATOR
Intervention: Chewing gum used 10 minutes prior to pain rating
Number of subjects: 60
Study 27341326 — intervention group
Group type: EXPERIMENTAL
Intervention: BalanceWear Therapy (BWT), weighted orthotic (WG), worn for 4 hours per day for 5 days
Number of subjects: 33
Study 27341326 — intervention group
Group type: COMPARATOR
Intervention: Sham BalanceWear Therapy (SWG), sham-weighted orthotic, worn for 4 hours per day for 5 days
Number of subjects: 33
Study 25622201 — intervention group
Group type: EXPERIMENTAL
Intervention: sibutramine
Number of subjects: 104
Study 25622201 — intervention group
Group type: EXPERIMENTAL
Intervention: self-help cognitive-behavioral therapy (shCBT) + sibutramine
Number of subjects: 104
Study 25622201 — intervention group
Group type: EXPERIMENTAL
Intervention: self-help cognitive-behavioral therapy (shCBT) + placebo
Number of subjects: 104
Study 25622201 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 104
Study 23299158 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.15 ug/kg
Number of subjects: 80
Study 23299158 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 1.5 ug/kg
Number of subjects: 80
Study 21888011 — intervention group
Group type: EXPERIMENTAL
Intervention: ODK‐0702
Number of subjects: 498
Study 19704058 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus Cetuximab (D + C)
Number of subjects: 59
Study 19704058 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus Bortezomib (D + B)
Number of subjects: 59
Study 16495192 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp electroacupuncture with Madopar
Number of subjects: 30
Study 16495192 — intervention group
Group type: COMPARATOR
Intervention: Madopar only (Control)
Number of subjects: 30
Study 14653129 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant growth hormone (rhGH) therapy (4 U per day for 7 days)
Number of subjects: 15
Study 14653129 — intervention group
Group type: COMPARATOR
Intervention: human albumin (10 g every other day for 3 times)
Number of subjects: 15
Study 10827559 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 0
Study 10827559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9124393 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (3 mg/kg bolus infusion over 5 min, followed by 50 µg x kg(‐1) x min(‐1) over 120 min)
Number of subjects: 8
Study 9124393 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (17 mg x kg(‐1) x min(‐1) over 30 min)
Number of subjects: 8
Study 9124393 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA
Number of subjects: 8
Study 9124393 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 8
Study 8310886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg post-evening meal (pem)
Number of subjects: 1672
Study 8310886 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 800 mg nocte
Number of subjects: 1672
Study 8310886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg nocte
Number of subjects: 1672
Study 8310886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine and cimetidine
Number of subjects: 1672
Study 3728026 — intervention group
Group type: EXPERIMENTAL
Intervention: Attest No. 1262 BI (ABI)
Number of subjects: 720
Study 3728026 — intervention group
Group type: COMPARATOR
Intervention: Swedish BI (SBI)
Number of subjects: 720
Study 30477864 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocetin 7.5 mg/day
Number of subjects: 30
Study 30477864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26653113 — intervention group
Group type: COMPARATOR
Intervention: NK3 receptor antagonist ESN364 (3-180 mg single dose)
Number of subjects: 65
Study 26653113 — intervention group
Group type: COMPARATOR
Intervention: NK3 receptor antagonist ESN364 (20, 60, or 180 mg daily for 10 days)
Number of subjects: 65
Study 26653113 — intervention group
Group type: COMPARATOR
Intervention: NK3 receptor antagonist ESN364 (20, 60, or 180 mg daily for 21 days)
Number of subjects: 65
Study 26653113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 25516360 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg/d for 3 months) with psychosocial intervention
Number of subjects: 32
Study 25516360 — intervention group
Group type: COMPARATOR
Intervention: Psychosocial intervention without donepezil
Number of subjects: 32
Study 22813677 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic Light
Number of subjects: 703
Study 22813677 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic Light+
Number of subjects: 703
Study 22813677 — intervention group
Group type: EXPERIMENTAL
Intervention: Facts Up Front
Number of subjects: 703
Study 22813677 — intervention group
Group type: EXPERIMENTAL
Intervention: Facts Up Front+
Number of subjects: 703
Study 22813677 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 703
Study 20337976 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolysed rice protein formula (HRPF)
Number of subjects: 92
Study 20337976 — intervention group
Group type: COMPARATOR
Intervention: Extensively hydrolysed cow's milk formula (EHF)
Number of subjects: 92
Study 18724153 — intervention group
Group type: EXPERIMENTAL
Intervention: Single rotational flap (group A, 19 eyes)
Number of subjects: 33
Study 18724153 — intervention group
Group type: EXPERIMENTAL
Intervention: Double sliding flaps (group B, 15 eyes)
Number of subjects: 33
Study 16382306 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (Lantus) subcutaneously at a dosage equal to the average of insulin/day administered in the preceding days of AN
Number of subjects: 21
Study 15189606 — intervention group
Group type: EXPERIMENTAL
Intervention: Task instructions that fit participants' implicit theory (fun or importance)
Number of subjects: 0
Study 15189606 — intervention group
Group type: COMPARATOR
Intervention: Task instructions that did not fit participants' implicit theory (fun or importance)
Number of subjects: 0
Study 12593425 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m MAA injection in cirrhosis patients
Number of subjects: 3
Study 12593425 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (11 subjects)
Number of subjects: 3
Study 9650539 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch delivering 11 mg/day
Number of subjects: 70
Study 9650539 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch delivering 22 mg/day
Number of subjects: 70
Study 9650539 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch delivering 44 mg/day
Number of subjects: 70
Study 9650539 — intervention group
Group type: COMPARATOR
Intervention: Baseline smoking rate
Number of subjects: 70
Study 8589208 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (2.5 mg/h for the first 48 hours, then 10 mg infused over 3 hours twice a day on days 3-7)
Number of subjects: 13
Study 8589208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 2572899 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily treatment with isoniazid (400 mg) and rifampicin (600 mg)
Number of subjects: 667
Study 2572899 — intervention group
Group type: COMPARATOR
Intervention: Twice-weekly treatment with isoniazid (900 mg) and rifampicin (600 mg)
Number of subjects: 667
Study 4824312 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery intervals of 1 min
Number of subjects: 24
Study 4824312 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery intervals of 2 min
Number of subjects: 24
Study 4824312 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery intervals of 4 min
Number of subjects: 24
Study 4824312 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery intervals of 6 min
Number of subjects: 24
Study 31884429 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 53
Study 31884429 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 53
Study 28739536 — intervention group
Group type: EXPERIMENTAL
Intervention: Time2bHealthy online healthy lifestyle program for parents (11-week program)
Number of subjects: 0
Study 26525004 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch-and-rinse in non-smokers (G1)
Number of subjects: 38
Study 26525004 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective enamel etching in non-smokers (G2)
Number of subjects: 38
Study 26525004 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch-and-rinse in smokers (G3)
Number of subjects: 38
Study 26525004 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective enamel etching in smokers (G4)
Number of subjects: 38
Study 23438094 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar cautery alone
Number of subjects: 60
Study 23438094 — intervention group
Group type: COMPARATOR
Intervention: Bipolar tissue sealant device
Number of subjects: 60
Study 23438094 — intervention group
Group type: COMPARATOR
Intervention: Control group (estimated blood loss)
Number of subjects: 60
Study 21600066 — intervention group
Group type: EXPERIMENTAL
Intervention: eBaViR (Wii Balance Board-based system), 20 one-hour sessions
Number of subjects: 17
Study 21600066 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 17
Study 19508250 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP&DOXY (scaling and root planing with 14% doxycycline gel applied subgingivally)
Number of subjects: 39
Study 19508250 — intervention group
Group type: COMPARATOR
Intervention: SRP (scaling and root planing)
Number of subjects: 39
Study 16536148 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide with rubber dam isolation
Number of subjects: 40
Study 16536148 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide without rubber dam isolation
Number of subjects: 40
Study 16536148 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive resin with rubber dam isolation
Number of subjects: 40
Study 16536148 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive resin without rubber dam isolation
Number of subjects: 40
Study 15120713 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE(1)
Number of subjects: 36
Study 15120713 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 36
Study 10709793 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher training programs (65 in-service programs)
Number of subjects: 500
Study 9108785 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg twice daily)
Number of subjects: 0
Study 9108785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9108785 — intervention group
Group type: COMPARATOR
Intervention: Combined placebo and lovastatin
Number of subjects: 0
Study 9108785 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment groups
Number of subjects: 0
Study 8185726 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (600 mg daily)
Number of subjects: 100
Study 8185726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8185726 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nonrunning control group)
Number of subjects: 100
Study 30067555 — intervention group
Group type: EXPERIMENTAL
Intervention: PNF lower-leg taping with treadmill training (PNFLT-TT)
Number of subjects: 27
Study 30067555 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training (TT)
Number of subjects: 27
Study 27271007 — intervention group
Group type: EXPERIMENTAL
Intervention: Design optimal for heterogeneous costs and homogeneous variances
Number of subjects: 0
Study 27271007 — intervention group
Group type: COMPARATOR
Intervention: Balanced design
Number of subjects: 0
Study 23412624 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot Humid (HH) environment
Number of subjects: 11
Study 23412624 — intervention group
Group type: COMPARATOR
Intervention: Hot Dry (HD) environment
Number of subjects: 11
Study 23412624 — intervention group
Group type: COMPARATOR
Intervention: Temperate (TEMP) environment
Number of subjects: 11
Study 21910937 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily rTMS (5 days/week for 4 weeks, 20 treatments in total)
Number of subjects: 77
Study 21910937 — intervention group
Group type: COMPARATOR
Intervention: Spaced rTMS (3 days/week for 6 weeks, 18 treatments in total)
Number of subjects: 77
Study 21910937 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Daily and Spaced rTMS)
Number of subjects: 77
Study 20592439 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback to website administrators about the quality of information on their website
Number of subjects: 52
Study 20592439 — intervention group
Group type: COMPARATOR
Intervention: Control group (websites that did not receive feedback)
Number of subjects: 52
Study 18757164 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV triage
Number of subjects: 106
Study 18757164 — intervention group
Group type: COMPARATOR
Intervention: Repeat Pap testing
Number of subjects: 106
Study 18757164 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 106
Study 16463694 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-beta-hexosaminidase (Hex) activity in synovial fluid of rheumatoid arthritis patients
Number of subjects: 54
Study 16463694 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-beta-hexosaminidase (Hex) activity in synovial fluid of osteoarthritis patients
Number of subjects: 54
Study 16463694 — intervention group
Group type: COMPARATOR
Intervention: N-acetyl-beta-hexosaminidase (Hex) activity in serum of all investigated groups
Number of subjects: 54
Study 16463694 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific activity of Hex in synovial fluid of rheumatoid arthritis patients
Number of subjects: 54
Study 12468134 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradot transdermal oestrogen patch (50 microg/day)
Number of subjects: 208
Study 12468134 — intervention group
Group type: COMPARATOR
Intervention: Menorest transdermal oestrogen patch (50 microg/day)
Number of subjects: 208
Study 10479159 — intervention group
Group type: EXPERIMENTAL
Intervention: WR 238605 (Tafenoquine) 300 mg daily for 7 days (Group A)
Number of subjects: 44
Study 10479159 — intervention group
Group type: EXPERIMENTAL
Intervention: WR 238605 (Tafenoquine) 500 mg daily for 3 days (Group B)
Number of subjects: 44
Study 10479159 — intervention group
Group type: EXPERIMENTAL
Intervention: WR 238605 (Tafenoquine) 1 dose of 500 mg (Group C)
Number of subjects: 44
Study 10479159 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine only (Group D)
Number of subjects: 44
Study 8568114 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% carbohydrate diet
Number of subjects: 25
Study 8568114 — intervention group
Group type: COMPARATOR
Intervention: 55% carbohydrate diet
Number of subjects: 25
Study 1720759 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating weekly chemotherapy regimen including Doxorubicin, vincristine, cyclophosphamide, bleomycin, intrathecal methotrexate and cytarabine, Methotrexate with leucovorin rescue, Ifosfamide with mesna, etoposide, and intrathecal methotrexate and cytarabine
Number of subjects: 75
Study 1720759 — intervention group
Group type: COMPARATOR
Intervention: One additional cycle or three monthly CHOP (consolidation treatment)
Number of subjects: 75
Study 6819029 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein energy supplement (energy and vitamins with 5-10% of energy from milk protein)
Number of subjects: 128
Study 6819029 — intervention group
Group type: COMPARATOR
Intervention: Vitamins only (a multivitamin sachet daily containing vitamins A, B, C, and D)
Number of subjects: 128
Study 6819029 — intervention group
Group type: COMPARATOR
Intervention: Energy (42-125 MJ from carbohydrate, plus vitamins)
Number of subjects: 128
Study 31289956 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-related endpoint - Disease Control Rate (DCR)
Number of subjects: 12
Study 31289956 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-related endpoint - Early Tumor Shrinkage (ETS)
Number of subjects: 12
Study 31289956 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-Free Survival (PFS)
Number of subjects: 12
Study 31289956 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-related endpoint - Overall Response Rate (ORR)
Number of subjects: 12
Study 29759808 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical nursing pathway (CNP)
Number of subjects: 118
Study 29759808 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing
Number of subjects: 118
Study 26931763 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site urine drug screening tests (OS-UDS) with training for GPs and supply of tests at medical offices.
Number of subjects: 1
Study 26931763 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard medical strategy for assessing drug use).
Number of subjects: 1
Study 24375296 — intervention group
Group type: EXPERIMENTAL
Intervention: D1 gastrectomy
Number of subjects: 267
Study 24375296 — intervention group
Group type: COMPARATOR
Intervention: D2 gastrectomy
Number of subjects: 267
Study 22310400 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematically aligned TKA
Number of subjects: 82
Study 22310400 — intervention group
Group type: COMPARATOR
Intervention: Mechanically aligned TKA
Number of subjects: 82
Study 20563294 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive treatment targets for LDL-C ≤70 mg/dL and systolic BP ≤115 mmHg
Number of subjects: 0